Your browser doesn't support javascript.
loading
LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism.
Ohara, Yuuki; Craig, Amanda J; Liu, Huaitian; Yang, Shouhui; Moreno, Paloma; Dorsey, Tiffany H; Cawley, Helen; Azizian, Azadeh; Gaedcke, Jochen; Ghadimi, Michael; Hanna, Nader; Ambs, Stefan; Hussain, S Perwez.
Afiliação
  • Ohara Y; Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Craig AJ; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Liu H; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Yang S; Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Moreno P; Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Dorsey TH; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Cawley H; Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Azizian A; Städtisches Klinikum Karlsruhe, Moltkestraße 90, 76133 Karlsruhe, Germany.
  • Gaedcke J; Städtisches Klinikum Karlsruhe, Moltkestraße 90, 76133 Karlsruhe, Germany.
  • Ghadimi M; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
  • Hanna N; Division of General and Oncologic Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Ambs S; Division of Surgical Oncology, Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Hussain SP; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Carcinogenesis ; 45(7): 475-486, 2024 Jul 08.
Article em En | MEDLINE | ID: mdl-38366633
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) encompasses diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, each exhibiting distinct characteristics, with the latter known for its aggressiveness. We employed an integrative approach combining transcriptome and metabolome analyses to pinpoint potential genes contributing to the basal-like/squamous subtype differentiation. Applying this approach to our NCI-UMD-German and a validation cohort, we identified LIM Domain Only 3 (LMO3), a transcription co-factor, as a candidate suppressor of the basal-like/squamous subtype. Reduced LMO3 expression was significantly associated with higher pathological grade, advanced disease stage, induction of the basal-like/squamous subtype and decreased survival among PDAC patients. In vitro experiments demonstrated that LMO3 transgene expression inhibited PDAC cell proliferation and migration/invasion, concurrently downregulating the basal-like/squamous gene signature. Metabolome analysis of patient tumors and PDAC cells revealed a metabolic program linked to elevated LMO3 and the classical/progenitor subtype, characterized by enhanced lipogenesis and suppressed amino acid metabolism. Notably, glycerol 3-phosphate (G3P) levels positively correlated with LMO3 expression and associated with improved patient survival. Furthermore, glycerol-3-phosphate dehydrogenase 1 (GPD1), a crucial enzyme in G3P synthesis, showed upregulation in LMO3-high and classical/progenitor PDAC, suggesting its potential role in mitigating disease aggressiveness. Collectively, our findings suggest that heightened LMO3 expression reduces transcriptome and metabolome characteristics indicative of basal-like/squamous tumors with decreased disease aggressiveness in PDAC patients. The observations describe LMO3 as a candidate for diagnostic and therapeutic targeting in PDAC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Regulação Neoplásica da Expressão Gênica / Carcinoma Ductal Pancreático / Proteínas Adaptadoras de Transdução de Sinal / Proliferação de Células / Proteínas com Domínio LIM Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Carcinogenesis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Regulação Neoplásica da Expressão Gênica / Carcinoma Ductal Pancreático / Proteínas Adaptadoras de Transdução de Sinal / Proliferação de Células / Proteínas com Domínio LIM Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Carcinogenesis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos